Research programme: TGF-beta 1 modulators - Janssen Biotech/Scholar Rock

Drug Profile

Research programme: TGF-beta 1 modulators - Janssen Biotech/Scholar Rock

Alternative Names: Niche activators - Janssen Biotech/Scholar Rock

Latest Information Update: 16 Jul 2015

Price : $50

At a glance

  • Originator Janssen Biotech; Scholar Rock
  • Class Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta1 inhibitors; Transforming growth factor beta1 modulators; Transforming growth factor beta1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 14 Jul 2015 Preclinical trials in Cancer in USA (unspecified route) prior to July 2015
  • 14 Jul 2015 Preclinical trials in Autoimmune disorders in USA (unspecified route) prior to July 2015
  • 08 Jan 2014 Early research in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top